James Baggs1, Kimberly Yousey-Hindes2, Elizabeth Dodds Ashley3, James Meek2, Ghinwa Dumyati3, Jessica Cohen4, Matthew E Wise5, L Clifford McDonald5, Fernanda C Lessa5. 1. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: jbaggs@cdc.gov. 2. Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, CT, United States. 3. University of Rochester Medical Center, Rochester, NY, United States. 4. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States; Atlanta Research and Education Foundation, Atlanta, GA, United States. 5. Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States.
Abstract
BACKGROUND: Efforts to develop a Clostridium difficile vaccine are underway; identification of patients at risk for C. difficile infection (CDI) is critical to inform vaccine trials. We identified groups at high risk of CDI ≥ 2 8 days after hospital discharge. METHODS: Hospital discharge data and pharmacy data from two large academic centers, in New York and Connecticut, were linked to active population-based CDI surveillance data from the Emerging Infections Program (EIP). Adult residents of the EIP surveillance area were included if they had an inpatient stay at a study hospital without prior history of CDI. The primary outcome was CDI by either toxin or molecular assay ≥ 28 days after an index hospitalization. Important predictors of CDI ≥ 28 days post discharge were initially identified through a Cox proportional hazards model (stepwise backward selection) using a derivation cohort; final model parameters were used to develop a risk score evaluated in the validation cohort. RESULTS: Of the 35,186 index hospitalizations, 288 (0.82%) had CDI ≥ 28 days post discharge. After parameter selection, age, number of hospitalizations in the prior 90 days, admission diagnosis, and the use of 3rd/4th generation cephalosporin, clindamycin or fluoroquinolone antibiotic classes remained in the model. Using the validation cohort, the risk score was predictive (p<0.001) with a c-score of 0.75. Based on the distribution of scores in the derivation cohort, we divided the patients into low and high risk groups. In the high risk group, 1.6% experienced CDI ≥ 28 days post discharge compared to 0.3% among our low risk group. CONCLUSIONS: Our study identified specific parameters for a risk score that can be applied at discharge to identify a patient population whose risk of CDI ≥ 28 days following an acute care hospitalization was 5 times greater than other patients. Published by Elsevier Ltd.
BACKGROUND: Efforts to develop a Clostridium difficile vaccine are underway; identification of patients at risk for C. difficileinfection (CDI) is critical to inform vaccine trials. We identified groups at high risk of CDI ≥ 2 8 days after hospital discharge. METHODS: Hospital discharge data and pharmacy data from two large academic centers, in New York and Connecticut, were linked to active population-based CDI surveillance data from the Emerging Infections Program (EIP). Adult residents of the EIP surveillance area were included if they had an inpatient stay at a study hospital without prior history of CDI. The primary outcome was CDI by either toxin or molecular assay ≥ 28 days after an index hospitalization. Important predictors of CDI ≥ 28 days post discharge were initially identified through a Cox proportional hazards model (stepwise backward selection) using a derivation cohort; final model parameters were used to develop a risk score evaluated in the validation cohort. RESULTS: Of the 35,186 index hospitalizations, 288 (0.82%) had CDI ≥ 28 days post discharge. After parameter selection, age, number of hospitalizations in the prior 90 days, admission diagnosis, and the use of 3rd/4th generation cephalosporin, clindamycin or fluoroquinolone antibiotic classes remained in the model. Using the validation cohort, the risk score was predictive (p<0.001) with a c-score of 0.75. Based on the distribution of scores in the derivation cohort, we divided the patients into low and high risk groups. In the high risk group, 1.6% experienced CDI ≥ 28 days post discharge compared to 0.3% among our low risk group. CONCLUSIONS: Our study identified specific parameters for a risk score that can be applied at discharge to identify a patient population whose risk of CDI ≥ 28 days following an acute care hospitalization was 5 times greater than other patients. Published by Elsevier Ltd.
Authors: Erik R Dubberke; Yan Yan; Kimberly A Reske; Anne M Butler; Joshua Doherty; Victor Pham; Victoria J Fraser Journal: Infect Control Hosp Epidemiol Date: 2011-04 Impact factor: 3.254
Authors: Fernanda C Lessa; Yi Mu; Wendy M Bamberg; Zintars G Beldavs; Ghinwa K Dumyati; John R Dunn; Monica M Farley; Stacy M Holzbauer; James I Meek; Erin C Phipps; Lucy E Wilson; Lisa G Winston; Jessica A Cohen; Brandi M Limbago; Scott K Fridkin; Dale N Gerding; L Clifford McDonald Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Aron J Hall; Aaron T Curns; L Clifford McDonald; Umesh D Parashar; Ben A Lopman Journal: Clin Infect Dis Date: 2012-04-04 Impact factor: 9.079
Authors: Scott Fridkin; James Baggs; Ryan Fagan; Shelley Magill; Lori A Pollack; Paul Malpiedi; Rachel Slayton; Karim Khader; Michael A Rubin; Makoto Jones; Matthew H Samore; Ghinwa Dumyati; Elizabeth Dodds-Ashley; James Meek; Kimberly Yousey-Hindes; John Jernigan; Nadine Shehab; Rosa Herrera; Clifford L McDonald; Amy Schneider; Arjun Srinivasan Journal: MMWR Morb Mortal Wkly Rep Date: 2014-03-07 Impact factor: 17.586
Authors: Monika Fischer; Dina Kao; Shama R Mehta; Tracey Martin; Joseph Dimitry; Ammar H Keshteli; Gwendolyn K Cook; Emmalee Phelps; Brian W Sipe; Huiping Xu; Colleen R Kelly Journal: Am J Gastroenterol Date: 2016-05-17 Impact factor: 10.864
Authors: Laurie Aukes; Bruce Fireman; Edwin Lewis; Julius Timbol; John Hansen; Holly Yu; Bing Cai; Elisa Gonzalez; Jody Lawrence; Nicola P Klein Journal: Open Forum Infect Dis Date: 2021-02-04 Impact factor: 3.835
Authors: K Ashley Jones; Udodirim N Onwubiko; Mary Elizabeth Sexton; Zanthia Wiley; Julianne Kubes; Benjamin Albrecht; Kristen Paciullo; Jessica Howard-Anderson; Sujit Suchindran; Ronald Trible; Jesse T Jacob; Sarah H Yi; Dana Goodenough; Scott K Fridkin Journal: Antimicrob Steward Healthc Epidemiol Date: 2021-10-22